Implantable Neurostimulators Market To Reach $9.87 Billion By 2030

Implantable Neurostimulators Market Growth & Trends

The global implantable neurostimulators market size is anticipated to reach USD 9.87 billion by 2030, expanding at a CAGR of 10.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of neurological diseases and higher occurrence of associated chronic pain and discomfort are driving the market.

The rising prevalence of neurological diseases such as Parkinson’s disease, epilepsy, essential tremor, chronic pain, and depression will result in increased demand for implantable neurostimulators. According to the WHO, in 2020, around 50.0 million people worldwide are suffering from epilepsy. Implanted neurostimulators are used to control epileptic seizures. Thus, increasing people suffering from epilepsy is expected to boost the market growth.

Moreover, the growing base of the aging population is more susceptible to neurological disorders, which is anticipated to be a high-impact rendering driver for this market. According to the CDC, Parkinson’s disease (PD) is mostly diagnosed in individuals above the age of 60 and it is projected that PD affects 1.0% of the people over the age of 60 to 4% by age of 80.

Furthermore, the incorporation of new technologies, and the introduction of new products by market players, is likely to boost the market during the forecast period. For instance, in September 2019, Abbott received U.S. FDA approval for its Proclaim XR recharge-free SCS system for the management of chronic pain.

 Request a free sample copy or view report summary: Implantable Neurostimulators Market Report

Implantable Neurostimulators Market Report Highlights

• The spinal cord stimulators segment dominated the market with a revenue share of 39.7% in 2024, driven by their effectiveness in managing chronic pain conditions. 

• The pain management segment dominated the market with the largest revenue share in 2024, which can be attributed to the prevalence of chronic pain disorders globally. 

• The hospitals & Ambulatory Surgery Centers (ASC) segment dominated the market with the largest revenue share in 2024, driven by their role as primary providers of advanced medical treatments. 

• North America implantable neurostimulators market dominated the global market with a revenue share of 43.7% in 2024, which can be attributed to the high prevalence of chronic pain conditions and neurological disorders in the region.

Implantable Neurostimulators Market Segmentation

Grand View Research has segmented the global implantable neurostimulators market on the basis of product type, application, end use, and region:

Implantable Neurostimulators Product Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Spinal Cord Stimulators

• Deep Brain Stimulators

• Sacral Nerve Stimulators

• Vagus Nerve Stimulators

• Gastric Electrical Stimulation

Implantable Neurostimulators Application Outlook (Revenue, USD Billion, 2018 - 2030)

• Pain Management

• Epilepsy

• Parkinson’s Disease

• Urinary and Fecal Incontinence

• Gastroparesis

• Others

Implantable Neurostimulators End Use Outlook (Revenue, USD Billion, 2018 - 2030)

• Hospitals & Ambulatory Surgery Centers (ASC)

• Clinics & Physiotherapy Centers

• Others

Implantable Neurostimulators Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.    

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Denmark

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Implantable Neurostimulators Market

• Abbott

• Medtronic

• Boston Scientific Corporation

• Aleva Neurotherapeutics

• Synapse Biomedical Inc.

• Nevro Corp.

• LivaNova PLC

• NeuroPace, Inc.

• Inspire Medical Systems, Inc.

• Cognito Therapeutics